Nov 2, 2023

DMC opens new lab in Research Triangle Park, NC – New 9,500 Square Foot R&D Facility

Morrisville, NC, 2 November 2023 – DMC Biotechnologies is announcing a new 9,500 square foot (880 square meter) metabolic engineering and fermentation facility in the Research Triangle Park (RTP) area of North Carolina, to support a team of scientists advancing DMC products and active collaborations.

The research and development lab employs a team of metabolic engineers, precision fermentation specialists, automation experts, and analytical support. The facility is home to DMC’s workflows in strain and metabolic engineering, high throughput testing, as well as bench and pilot scale fermentation. The RTP facility compliments DMC’s Boulder facility, which manages the company’s downstream separation and purification development activities.

DMC’s precision fermentation bioprocesses, which leverage its proprietary Dynamic Metabolic Control™ technology, enables the production of low carbon and economical chemicals. Improving the sustainability of chemicals is critical to mitigating future climate change.

Kenny Erdoes, DMC CEO said, “We are proud to announce the opening of our new laboratory in North Carolina. This new facility will support a growing team and enable us to bring online additional capabilities and streamline existing workflows to accelerate the development of new sustainable chemical solutions.”

North Carolina currently ranks among the top three U.S. states for bioscience employment and is a leader in vaccine research and manufacturing.

DMC media contact:
Kathryn Sheridan
Sustainability Consult
[email protected]
[email protected]

About DMC
DMC is a US bio-based chemical company that makes sustainably produced bio-based chemicals using
microbial fermentation. DMC’s proprietary Made to Scale™ technology platform makes fermentation
more standardized, robust, and predictable, transforming how the world makes chemicals.
DMC’s technology platform addresses the key barriers that have plagued the biotech industry for
decades including standardization, robustness, and predictability across scale. Addressing these
challenges translates to a dramatic reduction in the time to market and the investment needed to bring
products to commercialization.

For more information, visit: www.dmcbio.com

Other NEWS

DMC & Duke Receive NSF STTR Phase 1 Award

DMC & Duke Receive NSF STTR Phase 1 Award

STTR Phase I: Commercialization of Synthetic Metabolic Valves Award Information Agency: National Science Foundation Branch: N/A Contract: 1549624 Agency Tracking Number: 1549624 Amount: $225,000.00 Phase: Phase I Program: STTR Solicitation Topic Code: BT Solicitation...

read more
DMC & Duke Receive NSF STTR Phase 1 Award

DMC & Duke Receive NSF STTR Phase 1B Award

Award Abstract #1549624 STTR Phase I: Commercialization of Synthetic Metabolic Valves NSF Org: IIP Div Of Industrial Innovation & Partnersh Initial Amendment Date: December 18, 2015 Latest Amendment Date: December 23, 2016 Award Number: 1549624 Award Instrument:...

read more
DMC & Duke Receive NSF STTR Phase 1 Award

Duke and DMC Receive DOE Award for Innovative Bioenergy R&D

DOE Announces $10 Million for Innovative Bioenergy Research and Development The U.S. Department of Energy announced up to $10 million in funding for six projects representing innovative technologies and solutions to advance bioenergy development. These projects,...

read more